- Leading private equity firms 1315 Capital and Ampersand Capital Partners’ recent investment agreement with Interpace signal a “clear vote of confidence”
- Company’s business units, Interpace Diagnostics and Interpace Pharma Solutions, support the biotech and pharmaceutical sectors as they seek to improve early cancer diagnosis and promote increasingly effective therapies
- Life sciences industry forecast to reach $33.2 billion by 2024, experiencing an 11.5% CAGR over 5-year period
Interpace Biosciences (NASDAQ: IDXG), an evolving leader in the life sciences industry, recently entered into a $20 million investment agreement with two leading private equity firms investing in laboratory services (http://ibn.fm/G8cUU). The Series B Preferred stock investment consisting of $19 million and $1 million from 1315 Capital and Ampersand Capital Partners, respectively, will be a boon to IDXG’s growing power in an industry anticipated to reach $33.2 billion by 2024 – an increase from its $19.3 billion in 2019. The life sciences industry is forecast to experience a CAGR of 11.5% over the period (http://ibn.fm/H1lmI).
“We believe 1315 Capital will be, and Ampersand [a current investor] will continue to be, great partners for Interpace,” Interpace president and CEO Jack Stover stated in a news release. “This is a clear vote of confidence in Interpace and its diagnostic and pharma solutions businesses.”
In addition to the investment agreement, Interpace also announced its intention to effect a one-for-ten reverse stock split effective coincident with the former’s closing. The reverse stock split is meant to satisfy the Nasdaq Capital Market’s minimum bid price requirement by increasing the per share trading price of IDXG’s common stock. “We believe this proposed change in capital structure can benefit our stockholders and make our stock more attractive to institutional and other investors,” Stover noted.
Having assisted physicians in the diagnosis and treatment of over 75,000 patients, Interpace Biosciences has made contributions to some of the pharmaceutical and biotech industry’s most critical clinical trials (http://ibn.fm/ENyPi). Its business arms, Interpace Diagnostics™ and Interpace Pharma Solutions™, support the biomedical and oncological industries by empowering clinicians with complex molecular analysis data. This data helps enhance the efficacy of early cancer diagnosis and treatment, as well as supporting the development of targeted therapeutics.
Business unit Interpace Diagnostics™, focused on “resolving diagnostic uncertainty,” offers evidence-based, clinically beneficial molecular diagnostic tests and pathology services (http://ibn.fm/T04KG). Its offerings include reputable tests like PancraGen®, ThyGeNext®, ThyraMir®, RespriDX® and BarreGen®. The company’s tests assist in risk stratification of patient samples for a multitude of cancers, including thyroid, pancreatic and lung, among others. Results gleaned from these tests are used by physicians to make better, more effective treatment decisions that more accurately target each individual patient – determining whether patients are better suited for surgery or active surveillance. These recommendations have the potential to help health care professionals differentiate between potentially malignant cells and benign ones, thus saving patients from risky, expensive surgeries that are frequently unnecessary.
Alternatively, IDXG’s Interpace Pharma Solutions™ business unit works hand-in-glove with biopharmaceutical companies by providing lab testing, data management, project management and biorepository services (http://ibn.fm/joRK6). By utilizing Interpace Pharma Solutions’ scientific, medical and expert knowledge, biopharma and diagnostic clients are able to effectively integrate pharmacogenomics – the study of how genes affect a person’s response to drugs – into their drug development and clinical trial programs. Interpace Pharma Solutions’ platform generates logistical reports comprised of biomarker analysis, anatomic pathology, cytogenetics and customized molecular technologies (http://ibn.fm/619vG). As medicine personalized through the lens of genetics was recently referenced as one of the top trends in the life sciences industry (http://ibn.fm/KGwPA), Interpace Biosciences appears well-positioned to stay abreast of the dynamic industry and is an attractive option for pharmaceutical and biotech companies conducting or aiding in oncology-focused clinical trials.
Globally, the molecular diagnostics market is estimated to experience a CAGR of 8.7% during the forecast period from 2018 to 2024 (http://ibn.fm/6hNeA). With a comprehensive testing portfolio, Interpace Biosciences presents a convincing opportunity for investors looking to benefit from the global community’s growing reliance on personalized medicine.
For more information, visit the company’s website at www.Interpace.com
About MissionIR
MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
For more information, visit www.MissionIR.com
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
